Volume 11, Issue 10 (12-2013)                   IJRM 2013, 11(10): 837-0 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Torabizadeh A, Vahidroodsari F, Ghorbanpour Z. Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study. IJRM 2013; 11 (10) :837-0
URL: http://ijrm.ir/article-1-350-en.html
Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study
Aalie Torabizadeh1 , Fatemeh Vahidroodsari * 2, Zakieh Ghorbanpour3
1- Department of Obstetrics and Gynecology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2- Department of Obstetrics and Gynecology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran , sabalanmountain@yahoo.com
3- Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (2943 Views)
Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability.
Objective: Comparison of albumin and cabergoline in the prevention of OHSS.
Materials and Methods: 95 high risk infertile women for OHSS (more than 20 follicles in both ovaries at day of Human Chorionic Gonadotropin (HCG) injection) were randomly divided into two groups. First group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second group including 47 women received 0.5 mg/day dopamine agonist (Cabergolin) at day of HCG injection till 8 days. The dosage of human Menopausal Gonadotropin (HMG) used, total number of follicles developed, number of oocytes retrieved, serum E2 concentrations during the luteal phase, development of ascites, number of embryos generated, clinical pregnancy rate, results of the in vitro fertilization-embryo transfer (IVF-ET) cycles and incidence and severity of any OHSS were evaluated.
Results: There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergolin group (53.7%) versus albumin group (46.3%) (p=0.04). But there was no significant difference of a reduction in severe OHSS (p=0.62). There was no difference in clinical pregnancy rate too.
Conclusion: Administration of cabergolin can prevent incidence of OHSS and does not appear to effect on its severity. 
Keywords: Ovarian hyperstimulation syndrome (OHSS), Cabergolin, Assisted reproductive technology (ART), Albumin.
Full-Text [PDF 535 kb]   (587 Downloads) |   |   Full-Text (HTML)  (335 Views)  
Type of Study: Original Article |
References
1. Chen CD, Chen SU, Yang YS. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol 2012; 26: 817-827. [DOI:10.1016/j.bpobgyn.2012.04.004]
2. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15: 1037-1042. [DOI:10.1093/humrep/15.5.1037]
3. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; 94: 389-400. [DOI:10.1016/j.fertnstert.2010.03.028]
4. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade. Endocrinology 2002; 143: 4339-4348. [DOI:10.1210/en.2002-220204]
5. Albert C, Garrido N, Mercader A, Rao CV, Remohí J, Simón C, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 2002; 8: 409-418. [DOI:10.1093/molehr/8.5.409]
6. Janathan S. Berek "management of OHSS" textbook of novak .14th Ed. 2007, Chapter 30 pp; 1253-1254.
7. Speroff L, Robert H. Glass "ovarian hyperstimulation syndrome" textbook of clinical gynecology. 7th Ed. 2005. Chapter 32; pp:1250-1251.
8. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. serum anti-mullerian hormone and estradiol level as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Repord 2008; 23: 160-167. [DOI:10.1093/humrep/dem254]
9. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Repord 2007; 22: 766-771. [DOI:10.1093/humrep/del421]
10. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007; 5: 9. [DOI:10.1186/1477-7827-5-9]
11. Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Repord Update 2002; 8: 291-296. [DOI:10.1093/humupd/8.3.291]
12. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVFICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173-178. [DOI:10.1016/S1472-6483(10)60612-8]
13. Wada I, Matson PL, Troup SA, Morroll DR, Hunt L, Lieberman BA. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? Br J Obstet Gynaecol 1993; 100: 265-269. [DOI:10.1111/j.1471-0528.1993.tb15241.x]
14. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Repord 2002; 17: 2787-294. [DOI:10.1093/humrep/17.11.2787]
15. Suikkari AM. In-vito maturation: its role in fertility treatment. Curr Opin Obstet Gynecol 2008; 20: 242-248. [DOI:10.1097/GCO.0b013e3282f88e33]
16. Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) that is associated to associated to vascular hyperpermeability. Biol Reprod 2003; 68: 2164-2171. [DOI:10.1095/biolreprod.102.010801]
17. Garcia-Velasco JA. How to avoid ovarian hyperstimulation syndrome:a new indication for dopamine agonists. Repord Biomed Online 2009; 18: 71-75. [DOI:10.1016/S1472-6483(10)60452-X]
18. Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 1994; 62: 137-142. [DOI:10.1016/S0015-0282(16)56829-0]
19. McClelland DB. ABC of transfusion. Human albumin solutions. BMJ 1990; 300: 35-57. [DOI:10.1136/bmj.300.6716.35]
20. Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17: 3027-3032. [DOI:10.1093/humrep/17.12.3027]
21. Ben-Chetrit A, Eldar-Geva T, Gal M, Huerta M, Mimon T, Algur N, et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 2001; 16: 1880-1884. [DOI:10.1093/humrep/16.9.1880]
22. Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010; 16: 459-466. [DOI:10.1093/humupd/dmq006]
23. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008; 17: 751-755. [DOI:10.1016/S1472-6483(10)60401-4]
24. Bellver J, Mu-oz EA, Ballesteros A, Soares SR, Bosch E, Simón C, et al . Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 2003; 18: 2283-2288. [DOI:10.1093/humrep/deg451]
25. Tehraninejad ES, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 2012; 29: 259-264. [DOI:10.1007/s10815-011-9708-4]
26. Rollene NL, Amols MH, Hudson SB, Coddington CC. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009; 92: 1169. [DOI:10.1016/j.fertnstert.2009.05.062]
27. Shaltout A, Shohyab A, Youssef MA. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 2012; 165: 254-258. [DOI:10.1016/j.ejogrb.2012.08.008]
28. Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009; 92: 1168. [DOI:10.1016/j.fertnstert.2009.05.021]
29. Saylan A, Arioz DT, Koken T, Dilek H, Saylan F, Yilmazer M. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 2010; 89: 692-699. [DOI:10.3109/00016341003592537]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb